Equity Profile

NUVL

Nuvalent, Inc.

Health CareBiotechnology$8.7B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Although revenue estimates are not available, any growth in revenue would indicate successful product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. With a market cap of $9 billion, it operates in the health care sector, where innovation and advancements in treatment options are crucial for improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of -$1.39, slightly missing expectations. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's history of missing EPS estimates. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Nuvalent can demonstrate improved financial metrics or positive developments in its drug pipeline, it could lead to a strong recovery in stock price.

Bear Case

Continued losses and lack of revenue growth could further erode investor confidence, leading to a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of missing EPS estimates, this number will be crucial for investor sentiment and stock performance.

Is there any update on drug development progress?

Progress in drug development could significantly impact future revenue potential and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent's drug pipeline to yield positive results, despite recent losses.

Supporting Evidence

The lack of analyst estimates may indicate a broader uncertainty that could lead to a surprise in either direction.

Options pricing suggests a significant move, indicating that traders expect volatility that could be mispriced.

Key Risk

If the EPS comes in better than expected, it could shift the narrative and restore investor confidence.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the market is focused on whether Nuvalent can demonstrate progress in financial metrics and drug development.

Bull Confirmed If

A reduction in EPS loss to -$1.20 or better would signal improved financial health.

Bear Confirmed If

An EPS loss greater than -$1.50 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±3.9%

Historical Avg

±3.9%

In line with history

The options market is pricing in a potential move of about 3.9% in either direction, reflecting uncertainty around the earnings report.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$323,164.11

3,093 sh

1 insider

Net

$323,164.11

Net selling

Most Active Insiders· 2 open-market trades

Chief Scientific OfficerPelish Henry E.
$323,164.11

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations, history suggests the stock could rise by around 3.9%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react moderately, reflecting ongoing investor caution.

Miss

If the company misses expectations again, history suggests a potential drop of about 1.06%, further impacting investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timeline for drug trials and their expected outcomes.
2Management's commentary on cost management and financial strategy moving forward.
3Insights into market demand for their treatments and any partnerships.
4Any guidance on future revenue expectations or product launches.
5Responses to questions about recent insider selling and its implications.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Although revenue estimates are not available, any growth in revenue would indicate successful product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of -$1.39, slightly missing expectations. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's history of missing EPS estimates. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Nuvalent can demonstrate improved financial metrics or positive developments in its drug pipeline, it could lead to a strong recovery in stock price.

Bear Case

Continued losses and lack of revenue growth could further erode investor confidence, leading to a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of missing EPS estimates, this number will be crucial for investor sentiment and stock performance.

Is there any update on drug development progress?

Progress in drug development could significantly impact future revenue potential and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Nuvalent's drug pipeline to yield positive results, despite recent losses.

Supporting Evidence

The lack of analyst estimates may indicate a broader uncertainty that could lead to a surprise in either direction.

Options pricing suggests a significant move, indicating that traders expect volatility that could be mispriced.

Key Risk

If the EPS comes in better than expected, it could shift the narrative and restore investor confidence.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the market is focused on whether Nuvalent can demonstrate progress in financial metrics and drug development.

Bull Confirmed If

A reduction in EPS loss to -$1.20 or better would signal improved financial health.

Bear Confirmed If

An EPS loss greater than -$1.50 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±3.9%

Historical Avg

±3.9%

In line with history

The options market is pricing in a potential move of about 3.9% in either direction, reflecting uncertainty around the earnings report.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$323,164.11

3,093 sh

1 insider

Net

$323,164.11

Net selling

Most Active Insiders· 2 open-market trades

Chief Scientific OfficerPelish Henry E.
$323,164.11

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations, history suggests the stock could rise by around 3.9%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react moderately, reflecting ongoing investor caution.

Miss

If the company misses expectations again, history suggests a potential drop of about 1.06%, further impacting investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timeline for drug trials and their expected outcomes.
2Management's commentary on cost management and financial strategy moving forward.
3Insights into market demand for their treatments and any partnerships.
4Any guidance on future revenue expectations or product launches.
5Responses to questions about recent insider selling and its implications.